This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:othertreatments:birth_control [09.21.2011] – paulalbert | home:othertreatments:birth_control [01.03.2012] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 3: | Line 3: | ||
< | < | ||
- | Women of childbearing age on the MP who do not want to risk the chance of bearing a child suffering from fetal and neonatal injury, including hypotension, | + | Women of childbearing age on the MP who do not want to risk the chance of bearing a child suffering from fetal or neonatal injury should take precautions to prevent pregnancy, as the FDA package insert lists these as complications of taking olmesartan during the second or third trimesters. According to the FDA, these adverse effects do not appear to have resulted from intrauterine drug exposure that has occurred only during the first trimester. |
Because the MP can increase or restore fertility, women of childbearing age who are on the MP and sexually active are advised to use adequate precautions to avoid getting pregnant. | Because the MP can increase or restore fertility, women of childbearing age who are on the MP and sexually active are advised to use adequate precautions to avoid getting pregnant. | ||
Line 72: | Line 72: | ||
PMID: 9627916</ | PMID: 9627916</ | ||
- | EDIT | + |